智翔金泰跌2.22% 连亏4年半2023年上市募34.7亿

Core Viewpoint - Zhixiang Jintai (688443.SH) reported a significant increase in revenue but continued to face substantial net losses, indicating ongoing financial challenges despite recent capital raising efforts [1][2]. Financial Performance - In the first half of 2025, Zhixiang Jintai achieved operating revenue of 45.39 million yuan, a substantial increase from 0.0127 million yuan in the same period last year [1]. - The net profit attributable to shareholders was -289 million yuan, an improvement from -362 million yuan year-on-year [1]. - The company's net cash flow from operating activities was -116 million yuan, also an improvement from -264 million yuan in the previous year [1]. - The company has recorded losses for four consecutive years, with net profits attributable to shareholders from 2021 to 2024 being -322 million yuan, -576 million yuan, -801 million yuan, and -797 million yuan respectively [1]. IPO and Fundraising - Zhixiang Jintai went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, issuing 91.68 million new shares at a price of 37.88 yuan per share [1]. - The total amount raised from the IPO was approximately 3.47 billion yuan, with a net amount of about 3.29 billion yuan after deducting issuance costs, which was 688.6 million yuan less than the originally planned amount of 3.98 billion yuan [2]. - The funds raised are intended for the expansion of the antibody industrialization base and related research projects [2]. Issuance Costs - The total issuance costs for the IPO amounted to approximately 181.44 million yuan (excluding tax), with underwriting fees constituting about 164.96 million yuan [3].